Quantcast

Latest Fibrin Stories

2009-07-06 15:28:39

U.S. scientists say rare sheep called hair sheep could be a key to improving medical diagnostic tests conducted in the developing world. Hair sheep, the scientists said, do not have long, woolly coats that require shearing. But, more importantly, researchers at the Stanford University School of Medicine found not only are the sheep low-maintenance and parasite-resistant, they're also perfect blood donors for microbiology tests necessary to diagnose infectious disease in the developing world....

2009-06-18 01:00:00

SEATTLE, Washington, and LEIDEN, The Netherlands, June 18 /PRNewswire/ -- ProFibrix B.V. today announced the start of the company's Phase II clinical trial for Fibrocaps(TM), the company's lead topical Hemostat product, with the successful treatment of the first patients for mild to moderate bleeding during liver surgery. ProFibrix expects to complete the study before the end of 2009. Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin,...

2009-06-03 09:47:00

HAE:TSX Haemacure Completes US$2.5 Million Bridge Financing from Angiotech MONTREAL, June 3 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company, announces that Haemacure and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI, TSX:ANP) have today closed a senior secured bridge loan from Angiotech to Haemacure in a minimum amount of US$2.5 million. The loan was described in detail in Haemacure's press release of May 22, 2009. In...

2009-05-04 07:30:00

- Court Orders Confiscation of Diagnostica Stago's Inventory of Infringing Products - BEDFORD, Mass., May 4 /PRNewswire/ -- Instrumentation Laboratory Company and its parent company Instrumentation Laboratory S.p.A. (IL) today announced that the Paris First Level Civil Court determined that Diagnostica Stago infringed the French counterparts of two European patents licensed exclusively to IL, and committed acts of unfair competition due to denigrating advertisements. As a result, the Court...

2009-03-11 08:00:00

KING OF PRUSSIA, Pa., March 11 /PRNewswire/ -- CSL Behring has been informed by the U.S. Food and Drug Administration (FDA) that because RiaSTAP(TM) is the first FDA-approved treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, the company is entitled to seven years of orphan-drug exclusivity. RiaSTAP was approved by the FDA in January and is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including...

2009-03-05 16:00:00

SAN FRANCISCO, March 5 /PRNewswire-USNewswire/ -- Scleroderma is an autoimmune disease that leads to thickening and severe scarring of skin as well as thickening and failure of internal organs, including the lungs, heart, kidneys and intestines. The disease -- which the Scleroderma Foundation estimates affects approximately 300,000 Americans -- can be fatal and there is no cure. A major and incapacitating complication of scleroderma is the development of ulcers on the patients' fingers and...

2009-02-13 06:30:00

HAE:TSX MONTREAL, Feb. 13 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE) announces that it has implemented cost-cutting measures in order to preserve cash. At the same time, the Company will continue to seek financing and will initiate a process intended to lead to a sale or merger of the Company. Haemacure has been seeking financing since the third quarter of 2008. Several parties have expressed interest in an equity financing; however, this interest has not materialized into a...

2009-02-03 06:00:00

TSX: HAE MONTREAL, Feb. 3 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX: HAE) announced today that Joseph Galli, Chairman and Chief Executive Officer of Haemacure will present at the BIO CEO & Investor Conference, being held February 9-10 at the Waldorf-Astoria in New York City. Mr. Galli will present a corporate progress report, including an update on the Company's lead product candidate, Hemaseel(R)HMN (fibrin sealant). The Haemacure presentation is scheduled to begin at 10 AM...

2009-01-21 06:00:00

HAE:TSX MONTREAL, Jan. 21 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announces the results of the fiscal year ended October 31, 2008. Operational Highlights - Building and commissioning of a manufacturing facility - Commencement of plasma fractionation for lead product candidate, an all-human fibrin sealant - Positive...

2009-01-20 13:40:29

The U.S. Food and Drug Administration has approved RiaSTAP for the treatment of bleeding in patients with a rare genetic defect. People with the defect -- congenital fibrinogen deficiency -- are unable to make sufficient amounts of fibrinogen, which plays an important role in blood coagulation by helping to form blood clots and prevent bleeding. This product offers much-needed treatment for the small number of patients with congenital fibrinogen deficiency, said Dr. Jesse Goodman, director of...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related